Effect of two controller medications with inhaled corticosteroid in mild to moderate persistent asthma patients

Journal of Medical Sciences (Faisalabad)

Volumn 14, Issue 2, 2014, Pages 81-86

  Rajanandh, M G ^a   Nageswari, A D ^a   Ilango, K ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Asthma; Budesonide; Doxofylline; FEV1; Montelukast

Indexed keywords

BUDESONIDE; DOXOFYLLINE; MONTELUKAST;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODERATE PERSISTENT ASTHMA; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

EID: 84892612118     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2014.81.86     Document Type: Article

References (22)

1. Akbari, O., J.L Faul, E.G. Hoyte, G.J. Berry and J. Wahlstrom et al, 2006. CD4+ invariant T-cell-receptor+natural killer T cells in bronchial asthma. N. Engl. J. Med., 354: 1117-1129.
2. Antonicelli, L., C. Bucca, M. Neri, F. De Benedetto and P. Sabbatani et al, 2004. Asthma severity and medical resource utilization. Eur. Respir J., 23: 723-729.
3. Dupont, L., E. Potvin, D. Korn, A. Lachman and M. Dramaix et al, 2005. Improving asthma control in patients sub optimally controlled on inhaled steroids and long-acting b2-agonists: Addition of montelukast in an open-label pilot study. Curr. Med. Res. Opin., 21: 863-869.
4. + T lymphocytes and leukotriene B4: Novel interactions in the persistence and progression of asthma. J. Aller. Clm. Immunol, 117: 577-582.
5. Holgate, S.T. and R. Polosa, 2006. The mechanisms, diagnosis and management of severe asthma in adults. Lancet, 368: 780-793.
6. Jenkins, C.R., F.C. Thien, J.R. Wheatley and H.K. Reddel, 2005. Traditional and patient-centered outcomes with three classes of asthma medication. Eur. Respir J., 26: 36-44.
7. Keith, P.K., C. Koch, M. Djandji, J. Bouchard and E. Psaradellis et al, 2009. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting b-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (The RADAR Trial). Can. Respir J., 16: 17-31.
8. Korn, D., B.P. Vanden, E. Potvin, M. Dramaix, E. Herbots and R. Peche, 2009. Efficacy of add-on montelukast in patients with non-controlled asthma: A Belgian open-label study. Curr. Med. Res. Opin, 25: 489-497.
9. Leckie, M.J., A. Ten Brinke, J. Khan, Z. Diamant and B.J O'Connor et al, 2000. Effects of an interleukm-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet, 356: 2144-2148.
10. Leff, A.R., 2001. Regulation of leukotrienes in the management of asthma: Biology and clinical therapy. Ann. Rev. Med., 52: 1-14.
11. Lin, H., K.M. Boesel, D.T. Griffith, C. Prussm and B. Foster et al, 2004. Omalizumab rapidly decreases nasal allergic response and FcaRI onbasophils. J. Aller. Clm. Immunol, 113: 297-302.
12. Partridge, M.R. and S.R. Hill, 2000. Enhancing care for people with asthma: the role of communication, education, training and self-management: 1998 World Asthma Meeting Education and Delivery of Care Working Group. Eur. Respir. J., 16: 333-348.
13. Patel, Y.A., P. Patel, H. Bavadia, J. Dave and C.B. Tnpathi, 2010. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting [32 agonist in the treatment of moderate-to-severe persistent asthma. J. Postgr. Med., 56: 270-274.
14. Pauwels, R.A., S. Pedersen, W.W. Busse, W.C. Tan and Y.Z. Chen et al, 2003. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet, 361: 1071-1076.
15. Reiss, T.F., P. Chervinsky, R.J. Dockhorn, S. Shingo, B. Seidenberg and T.B. Edwards, 1998. Montelukast a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch. Intern Med., 158: 1213-1220.
16. Robinson, D.S., 2004. The role of the mast cell in asthma: Induction of airway hyperresponsiveness by interaction with smooth muscle? J. Allergy Clin. Immunol, 114: 58-65.
17. Rosenwasser, L.J. and J.A. Boyce, 2003. Mast cells: beyondIgE. J. Aller. Clm. Immunol, 111: 24-32.
18. Shah, A.R., L.D. Sharpies, R.N. Solanki and K.V. Shah, 2006. Double-blind, randomised, controlled trial assessing controller medications in asthma. Respiration, 73: 449-456.
19. Suissa, S., P. Ernst, S. Benayoun, M. Baltzan and B. Cai, 2000. Low-dose inhaled corticosteroids and the prevention of death from asthma. New Engl. J. Med., 343: 332-336.
20. Virchow, J.C., A. Prasse, I. Naya, L. Summerton and A. Harris, 2000. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med., 162: 578-585.
21. Virchow, J.C., A. Mehta, L. Ljungblad and H. Mitfessel, 2010. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast in Chronic Asthma (MONICA) study. Respir. Med., 104: 644-651.
22. Viswanathan, R., M. Prasad, A.K. Thakur, S.P. Sinha and N. Prakash et al, 1966. Epidemiology of asthma in an urban population. A random morbidity survey. J. Indian Med. Assoc, 46: 480-483.